Idursulfase - Latest Advances

Genotype-Phenotype Correlations and Shifting Diagnosis Age in Turkish Mucopolysaccharidosis Type II Patients: A Multicenter Retrospective Study.

Journal: Diagnostics (Basel, Switzerland)

Published: September 30, 2025

Novel Phenotypic Insights into the IDS c.817C>T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts.

Journal: International journal of neonatal screening

Published: July 18, 2025

Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the Hunter Outcome Survey.

Journal: Molecular genetics and metabolism

Published: July 04, 2025

Case report of neuronopathic mucopolysaccharidosis type II: Early intracerebroventricular enzyme replacement therapy and hematopoietic cell transplantation with developmental outcomes up to 5 years of age.

Journal: Molecular genetics and metabolism reports

Published: June 04, 2025

Site-specific characterization of mannose-6-phosphate-containing N-glycans on recombinant idursulfase beta for lysosomal targeting in Hunter syndrome therapy.

Journal: International journal of biological macromolecules

Published: June 02, 2025

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Journal: Cureus

Published: May 12, 2025

Female Patients With Mucopolysaccharidosis II (MPS II): Insights From the Hunter Outcome Survey.

Journal: JIMD reports

Published: April 25, 2025

Hypersensitivity Reaction and a Single-Bag Rapid Desensitization to Idursulfase.

Journal: American journal of medical genetics. Part A

Published: January 27, 2025

A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase.

Journal: Molecular genetics and metabolism

Published: October 25, 2024

Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort.

Journal: Genetics in medicine : official journal of the American College of Medical Genetics

Published: October 22, 2024

Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II.

Journal: PloS one

Published: September 01, 2024

Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.

Journal: International journal of molecular sciences

Published: June 28, 2024

Filters

Genotype-Phenotype Correlations and Shifting Diagnosis Age in Turkish Mucopolysaccharidosis Type II Patients: A Multicenter Retrospective Study.

Genotype-Phenotype Correlations and Shifting Diagnosis Age in Turkish Mucopolysaccharidosis Type II Patients: A Multicenter Retrospective Study.

Novel Phenotypic Insights into the IDS c.817C>T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts.

Novel Phenotypic Insights into the IDS c.817C>T Variant in Mucopolysaccharidosis Type II from Newborn Screening Cohorts.

Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the Hunter Outcome Survey.

Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the Hunter Outcome Survey.

Case report of neuronopathic mucopolysaccharidosis type II: Early intracerebroventricular enzyme replacement therapy and hematopoietic cell transplantation with developmental outcomes up to 5 years of age.

Case report of neuronopathic mucopolysaccharidosis type II: Early intracerebroventricular enzyme replacement therapy and hematopoietic cell transplantation with developmental outcomes up to 5 years of age.

Site-specific characterization of mannose-6-phosphate-containing N-glycans on recombinant idursulfase beta for lysosomal targeting in Hunter syndrome therapy.

Site-specific characterization of mannose-6-phosphate-containing N-glycans on recombinant idursulfase beta for lysosomal targeting in Hunter syndrome therapy.

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Carpal Tunnel Syndrome Attributed to Medication Use: A Pharmacovigilance Study.

Female Patients With Mucopolysaccharidosis II (MPS II): Insights From the Hunter Outcome Survey.

Female Patients With Mucopolysaccharidosis II (MPS II): Insights From the Hunter Outcome Survey.

Hypersensitivity Reaction and a Single-Bag Rapid Desensitization to Idursulfase.

Hypersensitivity Reaction and a Single-Bag Rapid Desensitization to Idursulfase.

A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase.

A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2/3 clinical trial and extension study of intrathecal idursulfase.

Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort.

Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort.

Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II.

Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II.

Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.

Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.